Fortmann, Mats Ingmar
Dirks, Johannes
Goedicke-Fritz, Sybelle
Liese, Johannes
Zemlin, Michael
Morbach, Henner
Härtel, Christoph
Funding for this research was provided by:
BMBF (01GL1746B)
Universitätsklinikum Würzburg
Article History
Received: 10 February 2022
Accepted: 8 July 2022
First Online: 3 August 2022
Declarations
:
: Dr. Fortmann has been supported by a clinician scientist stipend by the University of Lübeck and the German Center of Infection Research funded by the German Federal Ministry of Education and Research (BMBF). Dr. Dirks received a clinical scientist stipend from the University of Würzburg. Dr. Liese reported receiving grants from BMBF GlaxoSmithKline, Janssen-Cilag, Pfizer, MSD, and Sanofi-Pasteur outside the submitted work. Dr. Morbach received grants from DFG. Dr. Zemlin received grants BMBF and DFG. Dr. Härtel received grants from BMBF, EU, DFG and a Chiesi research stipend. Dr. Zemlin and Dr. Härtel are principal investigators of the PRIMAL consortium which investigates priming immunity at the beginning of life including the interactions between microbiome and vaccine responses in preterm babies. There are no other conflicts of interest relevant to this article to disclose.